Omeros' IgA nephropathy candidate gets FDA breakthrough designation

FDA granted breakthrough therapy designation to OMS721 from Omeros Corp. (NASDAQ:OMER) to treat IgA nephropathy. Omeros is evaluating the human mAb against mannan binding lectin serine peptidase 2 (M...